CLEARBRIDGE HEALTH LIMITED

(Company Registration No. 201001436C) (the "**Company**")

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE LISTING MANUAL - CORRIGENDUM

The board of directors (the "Board" or the "Directors") of Clearbridge Health Limited (the "Company") wishes to inform that the following transaction was inadvertently omitted from the Company's announcement in relation to Rule 706A of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") dated 26 February 2021.

Incorporation of subsidiary in China

On 9 September 2020, Shanghai Kaizhun Health Management Co. Ltd., a wholly-owned subsidiary of the Company, had incorporated a wholly-owned subsidiary in China known as Red Dot Health Technology (Shanghai) Co. Ltd ("Red Dot") (the "Incorporation").

As at the date of this announcement, the issued and paid-up capital of Red Dot is RMB50,000 and the net asset value is RMB50,000. The principal business activity of Red Dot is the distribution of medical and lifestyle products.

The Incorporation was funded through internal resources and it is not expected to have any material impact on the net tangible assets and earnings per shares of the Group for the financial year ending 31 December 2020.

None of the Directors or controlling shareholders of the Company and their respective associates has any interest, direct or indirect, in the Incorporation, save for their shareholdings in the Company, if any.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Chief Executive Officer and Executive Director

1 March 2021

This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.